Literature DB >> 26811325

Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.

Madeleine J Oudin1, Oliver Jonas1, Tatsiana Kosciuk1, Liliane C Broye1, Bruna C Guido1, Jeff Wyckoff1, Daisy Riquelme1, John M Lamar1, Sreeja B Asokan2, Charlie Whittaker1, Duanduan Ma1, Robert Langer1, Michael J Cima1, Kari B Wisinski3, Richard O Hynes4, Douglas A Lauffenburger5, Patricia J Keely6, James E Bear7, Frank B Gertler8.   

Abstract

UNLABELLED: Fibronectin (FN) is a major component of the tumor microenvironment, but its role in promoting metastasis is incompletely understood. Here, we show that FN gradients elicit directional movement of breast cancer cells, in vitro and in vivo Haptotaxis on FN gradients requires direct interaction between α5β1 integrin and MENA, an actin regulator, and involves increases in focal complex signaling and tumor cell-mediated extracellular matrix (ECM) remodeling. Compared with MENA, higher levels of the prometastatic MENA(INV) isoform associate with α5, which enables 3-D haptotaxis of tumor cells toward the high FN concentrations typically present in perivascular space and in the periphery of breast tumor tissue. MENA(INV) and FN levels were correlated in two breast cancer cohorts, and high levels of MENA(INV) were significantly associated with increased tumor recurrence as well as decreased patient survival. Our results identify a novel tumor cell-intrinsic mechanism that promotes metastasis through ECM remodeling and ECM-guided directional migration. SIGNIFICANCE: Here, we provide new insight into how tumor cell:ECM interactions generate signals and structures that promote directed tumor cell migration, a critical component of metastasis. Our results identify a tumor cell-intrinsic mechanism driven by the actin regulatory protein MENA that promotes ECM remodeling and haptotaxis along FN gradients. Cancer Discov; 6(5); 516-31. ©2016 AACR.See related commentary by Santiago-Medina and Yang, p. 474This article is highlighted in the In This Issue feature, p. 461. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26811325      PMCID: PMC4854754          DOI: 10.1158/2159-8290.CD-15-1183

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  45 in total

1.  Characterization of the expression of the pro-metastatic Mena(INV) isoform during breast tumor progression.

Authors:  Madeleine J Oudin; Shannon K Hughes; Nazanin Rohani; Mira N Moufarrej; Joan G Jones; John S Condeelis; Douglas A Lauffenburger; Frank B Gertler
Journal:  Clin Exp Metastasis       Date:  2015-12-17       Impact factor: 5.150

Review 2.  The extracellular matrix modulates the hallmarks of cancer.

Authors:  Michael W Pickup; Janna K Mouw; Valerie M Weaver
Journal:  EMBO Rep       Date:  2014-11-08       Impact factor: 8.807

3.  Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration.

Authors:  Jeanine Pignatelli; Sumanta Goswami; Joan G Jones; Thomas E Rohan; Evan Pieri; Xiaoming Chen; Esther Adler; Dianne Cox; Sara Maleki; Anne Bresnick; Frank B Gertler; John S Condeelis; Maja H Oktay
Journal:  Sci Signal       Date:  2014-11-25       Impact factor: 8.192

4.  Mesenchymal chemotaxis requires selective inactivation of myosin II at the leading edge via a noncanonical PLCγ/PKCα pathway.

Authors:  Sreeja B Asokan; Heath E Johnson; Anisur Rahman; Samantha J King; Jeremy D Rotty; Irina P Lebedeva; Jason M Haugh; James E Bear
Journal:  Dev Cell       Date:  2014-12-04       Impact factor: 12.270

5.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.

Authors:  Elaine Y Lin; Joan G Jones; Ping Li; Liyin Zhu; Kathleen D Whitney; William J Muller; Jeffrey W Pollard
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

6.  A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors.

Authors:  Jeffrey Wyckoff; Weigang Wang; Elaine Y Lin; Yarong Wang; Fiona Pixley; E Richard Stanley; Thomas Graf; Jeffrey W Pollard; Jeffrey Segall; John Condeelis
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

7.  Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis.

Authors:  Sophie Astrof; Denise Crowley; Elizabeth L George; Tomohiko Fukuda; Kiyotoshi Sekiguchi; Douglas Hanahan; Richard O Hynes
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

8.  Role of fibronectin in collagen deposition: Fab' to the gelatin-binding domain of fibronectin inhibits both fibronectin and collagen organization in fibroblast extracellular matrix.

Authors:  J A McDonald; D G Kelley; T J Broekelmann
Journal:  J Cell Biol       Date:  1982-02       Impact factor: 10.539

9.  Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters.

Authors:  Alexandra Naba; Karl R Clauser; John M Lamar; Steven A Carr; Richard O Hynes
Journal:  Elife       Date:  2014-03-11       Impact factor: 8.140

10.  LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues.

Authors:  Keefe T Chan; Sreeja B Asokan; Samantha J King; Tao Bo; Evan S Dubose; Wenjin Liu; Matthew E Berginski; Jeremy M Simon; Ian J Davis; Shawn M Gomez; Norman E Sharpless; James E Bear
Journal:  J Cell Biol       Date:  2014-10-27       Impact factor: 10.539

View more
  78 in total

1.  Three-dimensional Image-based Mechanical Modeling for Predicting the Response of Breast Cancer to Neoadjuvant Therapy.

Authors:  Jared A Weis; Michael I Miga; Thomas E Yankeelov
Journal:  Comput Methods Appl Mech Eng       Date:  2016-09-01       Impact factor: 6.756

2.  Functionally graded biomaterials for use as model systems and replacement tissues.

Authors:  Jeremy M Lowen; J Kent Leach
Journal:  Adv Funct Mater       Date:  2020-03-04       Impact factor: 18.808

Review 3.  The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy.

Authors:  Miles Piper; Adam C Mueller; Sana D Karam
Journal:  Mol Carcinog       Date:  2020-05-04       Impact factor: 4.784

4.  Transient mechanical strain promotes the maturation of invadopodia and enhances cancer cell invasion in vitro.

Authors:  Alexander N Gasparski; Snehal Ozarkar; Karen A Beningo
Journal:  J Cell Sci       Date:  2017-04-26       Impact factor: 5.285

5.  The tumor cell-secreted matricellular protein WISP1 drives pro-metastatic collagen linearization.

Authors:  Hong Jia; Jagadeesh Janjanam; Sharon C Wu; Ruishan Wang; Glendin Pano; Marina Celestine; Ophelie Martinot; Hannah Breeze-Jones; Georgia Clayton; Cecile Garcin; Abbas Shirinifard; Ana Maria Zaske; David Finkelstein; Myriam Labelle
Journal:  EMBO J       Date:  2019-07-11       Impact factor: 11.598

6.  Bioelectric Control of Metastasis in Solid Tumors.

Authors:  Samantha L Payne; Michael Levin; Madeleine J Oudin
Journal:  Bioelectricity       Date:  2019-09-16

7.  Arp2/3 Complex Is Required for Macrophage Integrin Functions but Is Dispensable for FcR Phagocytosis and In Vivo Motility.

Authors:  Jeremy D Rotty; Hailey E Brighton; Stephanie L Craig; Sreeja B Asokan; Ning Cheng; Jenny P Ting; James E Bear
Journal:  Dev Cell       Date:  2017-08-31       Impact factor: 12.270

Review 8.  Balancing forces in migration.

Authors:  Patrick W Oakes
Journal:  Curr Opin Cell Biol       Date:  2018-05-23       Impact factor: 8.382

9.  Integrin αvβ3-associated DAAM1 is essential for collagen-induced invadopodia extension and cell haptotaxis in breast cancer cells.

Authors:  Ting Yan; Ailiang Zhang; Fangfang Shi; Fei Chang; Jie Mei; Yongjian Liu; Yichao Zhu
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

10.  MENA Promotes Tumor-Intrinsic Metastasis through ECM Remodeling and Haptotaxis.

Authors:  Miguel Santiago-Medina; Jing Yang
Journal:  Cancer Discov       Date:  2016-05       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.